CCL18 and endometrial cancer: The studies included have demonstrated a downregulation of epithelial marker E-cadherin in endometrial cancer cells by TGF-β treatment [65,80,96,99], AMF treatment [103], and IL-6 treatment [65] and when treated with chemokine CCL18 [100] and RANK/RANKL/CCL20 [102].